ATACAND
Clinical safety rating
cautionComprehensive clinical and safety monograph for ATACAND (ATACAND).
Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
| Metabolism | Candesartan is primarily metabolized by ester hydrolysis to its active metabolite, candesartan, and further undergoes O-deethylation by CYP2C9 (minor route). |
| Excretion | Renal (60% unchanged), biliary/fecal (40% as camdhesartan). Approximately 33% of the dose is excreted in urine as unchanged drug, and the remainder as inactive metabolites via bile and feces. |
| Half-life | Terminal half-life is approximately 9 hours (range 5-11 hours). In elderly patients, half-life may be prolonged. No accumulation upon repeated dosing. |
| Protein binding | High protein binding: >99%, primarily to serum albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 0.13 L/kg (mean 9 L). This low Vd indicates limited extravascular distribution, consistent with high plasma protein binding. |
| Bioavailability | Absolute oral bioavailability is approximately 15% (prodrug candesartan cilexetil is completely converted to active candesartan during absorption). Food does not affect bioavailability. |
| Onset of Action | Oral: Onset of antihypertensive effect occurs within 2 hours, with peak effect at 4-8 hours. |
| Duration of Action | Duration of action is approximately 24 hours, allowing once-daily dosing for hypertension. Blood pressure reduction is maintained over 24 hours with minimal trough-to-peak ratio. |
| Molecular Weight | 610.7 |
Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.
| Dosage form | TABLET |
| Renal impairment | No initial dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min (including dialysis), initiate at 4 mg once daily and titrate cautiously with monitoring. |
| Liver impairment | For Child-Pugh Class A or B: initiate at 4 mg once daily and titrate cautiously. Child-Pugh Class C: not recommended (no data). |
| Pediatric use | For children ≥1 year and <6 years: 0.2-0.4 mg/kg/day once daily or divided twice daily; maximum 0.6 mg/kg/day (up to 32 mg/day). For children ≥6 years: 4-8 mg once initially; may increase to 16 mg once daily (or 32 mg daily in larger children). |
| Geriatric use | Start at 4 mg once daily in patients ≥75 years; adjust based on blood pressure response and renal function (e.g., GFR <30 mL/min). |
| 1st trimester | Associated with fetal renal impairment, oligohydramnios, and skull ossification defects; risk of teratogenicity is low but not zero; use not recommended. |
| 2nd trimester | Contraindicated: may cause oligohydramnios, fetal renal dysfunction, and neonatal renal failure. |
| 3rd trimester | Contraindicated: can cause fetal hypotension, hyperkalemia, and irreversible renal damage; oligohydramnios may lead to contractures, limb deformities, and pulmonary hypoplasia. |
Clinical note
Comprehensive clinical and safety monograph for ATACAND (ATACAND).
| Placental transfer | Crosses placenta; detected in fetal circulation; known to cause fetal renin-angiotensin system suppression. |
| Breastfeeding | No data on excretion in human milk; avoid use due to potential risk of neonatal hypotension and renal impairment. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, skull ossification defects, hypotension, anuria) due to direct renin-angiotensin system blockade. Risk of neonatal renal failure and hypotension if exposed after 20 weeks gestation. |
| Fetal Monitoring | Maternal: Blood pressure, serum creatinine, potassium, and urine output. Fetal: Serial ultrasound assessment of amniotic fluid volume, fetal renal anatomy, and growth after 20 weeks gestation. Neonatal: Monitoring for hypotension, oliguria, hyperkalemia, and renal function for 48-72 hours post-delivery if exposed in utero. |
| Fertility Effects | No specific human fertility data. Animal studies show no adverse effects on fertility. Theoretical risk due to hemodynamic changes, but no evidence of direct gonadal toxicity. |
■ FDA Black Box Warning
When pregnancy is detected, discontinue ATACAND as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
| Serious Effects |
Pregnancy (especially second and third trimesters)Hypersensitivity to candesartan or any componentHistory of angioedema with previous ACE inhibitor or ARB therapyConcomitant use with aliskiren in patients with diabetes mellitus
| Precautions | Hypotension: Symptomatic hypotension may occur in volume-depleted patients or those with heart failure., Hyperkalemia: Monitor serum potassium, especially in patients with renal impairment or on potassium-sparing diuretics., Renal impairment: Use caution in patients with renal artery stenosis or severe renal impairment; monitor renal function., Fetal/neonatal morbidity and mortality: As noted in black box warning., Avoid use in patients with bilateral renal artery stenosis or unilateral stenosis in a solitary kidney. |
| Food/Dietary | No significant food interactions. Avoid potassium-rich foods (e.g., bananas, oranges, spinach, avocados) in large amounts if also taking potassium supplements or potassium-sparing diuretics. Salt substitutes containing potassium chloride should be used cautiously. |
| Clinical Pearls | ATACAND (candesartan cilexetil) is an angiotensin II receptor blocker (ARB) used primarily for hypertension and heart failure. Monitor renal function and electrolytes, especially potassium, within 2-4 weeks of initiation or dose adjustment. Avoid use in pregnancy (Category D). May cause angioedema; discontinue immediately if occurs. Dual blockade with ACE inhibitors or aliskiren increases risk of hypotension, hyperkalemia, and renal impairment. |
| Patient Advice | Take ATACAND exactly as prescribed, typically once daily with or without food. · Do not use if pregnant or planning pregnancy; consult doctor immediately if pregnancy occurs. · May cause dizziness or lightheadedness, especially during initial therapy; avoid driving until effects are known. · Avoid potassium supplements or salt substitutes containing potassium unless directed by healthcare provider. · Report signs of angioedema (swelling of face, lips, throat, difficulty breathing) or fainting to physician immediately. · Maintain adequate hydration and avoid dehydration (excessive sweating, vomiting, diarrhea). |
Loading safety data…